The first cholesterol-lowering medication in a new class of drugs—proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors—has received FDA approval.
Alirocumab, marketed as Praluent, is approved for use along with diet and statin therapy by adults with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease whose low-density lipoprotein (LDL) cholesterol level is too high (http://1.usa.gov/1CZvYDg).
Voelker R. New Drug to Lower LDL Cholesterol. JAMA. 2015;314(9):867. doi:10.1001/jama.2015.10491